Jan Philippé. VAKB 3 februari 2014
|
|
- Phillip Bradford
- 6 years ago
- Views:
Transcription
1 Jan Philippé VAKB 3 februari 2014
2 DISEASE (+ MRD) NR of Citations (pubmed) 1st cited Author / journal (1st) ALL Hoelzer / Blood AML Hagenbeek / Leukemia CLL Dighiero / Leuk Lymphoma Multiple myeloma Follicular lymphoma Yeh / BJH Miyamura / Rinsho Ketsueki HCL Filleul / Leukemia MCL Corradieri / Blood
3 MRD during and at the end of therapy is a powerful predictor of PFS and OS In CLL and MM, at least, this predictor appears to be independent of clinical response, type or line of therapy, and other known biological markers Clinical trials are running to assess whether MRD can be used for guiding therapies
4 Molecular analyses ASO RQ-PCR of the junctional region of the rearranged IgH genes Analytical sensitivity: Applicability: ~80% Expertise: ++ Cost: ++ Speed: weeks PCR of the chromosomal translocations t(11; 14) in MCL (RQ-PCR) Analytical sensitivity: Applicability: 50% t(14;18) in foll lymph (RQ-PCR or nested PCR) Analytical sensitivity: Applicability: ±70% Expertise: + Cost: + Speed: days week(s)
5 Flow Cytometric analyses Multiparameter FC Sensitivity: 10-4 Applicability: >90% Expertise: ++ Cost: + Speed: one or 2 days
6 Comparison ASO RQ PCR vs FC in CLL MRD in CLL1/9 FC & PCR are equally effective for MRD quantification with sensitivity 10-4 PCR is more sensitive for MRD <10-4 Böttcher et al. Leukemia 2009
7 MRD in CLL2/9 Leukemia (2007) (Rawstron A. et al) 5 tube 4 CLR setup ERIC (European Research Initiative in CLL) update : Leukemia 2013 (Rawstron A. et al) MRD screening with Full MRD analysis with 1 tube, 4 CLR 2 tubes, 6 CLR
8 MRD in CLL3/9 CD5+ B-cells:29% κ/λ: 0,33/1 sig neg 19+5+: 11%
9 MRD in CLL4/9
10 MRD in CLL5/9 Why are such large deviations from normal required? Regenerating B cells have high levels of CD5 Highly skewed κ:λ ratios in the early stages after treatment Lack of sig on the CD5+ B cells varies between pts How frequent is screening + in a series of analyses? if > 1% CLL cells (according to full MRD) 72% if < 1% CLL cells (according to full MRD) 37% on average 50% of screening is +, with 100% PPV!
11 MRD in CLL6/9
12 MRD in CLL7/9
13 When is this full panel needed? In about 50% of cases the criteria as defined for the MRD screening are not met What are the strenghts of 2x 6 CLR? cost, time, complexity, permits acquisition of events Detection limit: 10-4 à 10-5 Quantitative Weaknesses? Differences between labs? MRD in CLL8/9
14 MRD in CLL9/9 EUROFLOW will propose. Fully standardized instruments Fully standardized staining protocols Use of library of phenotypes Use of gatings in plots obtained by PCA A. Langerak & S. Böttcher developed a new panel: validation will follow soon in 3 centers among which UZ Gent EuroClonality (a division of ESHLO) NGS Consortium on Next-Generation Sequencing for IG / TR immunogenetic analysis Coordinator: A. Langerak Main objectives are to develop, standardize, and validate IG/TR NGS assays for clonality assessment, MRD analysis, and repertoire analysis
15 MRD in MM1/9 Molecular analyses ASO RQ-PCR of the junctional region of the rearranged IgH genes Sensitivity: Applicability: ~40% Expertise: ++ Cost: ++ Speed: weeks Multiparameter FC Sensitivity: 10-4 Applicability: >90% Expertise: ++ Cost: + Speed: days
16 MRD in MM2/9 Reasons for low applicability in ASO RQ- PCR Lack of clonality detection (20%) Unsuccessful sequencing (10%) Suboptimal ASO performance (30%)
17 MRD in MM3/9 Puig N. et al. Leukemia 2013
18 MRD in MM4/9
19 MRD in MM5/9
20 MRD in MM6/9 Robillard et al. Blood Canc J 2013
21 MRD in MM7/9 Conclusions of the Nancy study: Millions of cells are needed to start with 7 CLR analysis has a lower sensitivity (10-5 ) This approach does not depend upon the initial phenotype Aberrant phenotypes may be found in healthy donors Thus proof of clonality is mandatory! Open question Quantitative? (variability in MM cells in aspirate) Pre-analytical problem
22 MRD in MM8/9 EUROFLOW will propose. Fully standardized instruments/protocols Use of plots based upon PCA A disease-specific approach (not patient-specific) Usage of pre-defined data bases of normal reactive PC phenotypes Other markers? (CD27, CD81,..) EuroClonality (a division of ESHLO) NGS Consortium on Next-Generation Sequencing for IG / TCR immunogenetic analysis Coordinator: Anton W. Langerak Main objectives are to develop, standardize, and validate IG/TR NGS assays for clonality assessment, MRD analysis, and repertoire analysis
23 MRD in MM9/9 -A high correlation between NGS and PCR MRD, -MRD-negativity in PBSC autografts by NGS may be more closely associated with durable remission than that revealed by ASO-qPCR Takamatsu et al. Abstract ASH 2013
24 Dank voor uw aandacht Vragen??
Translocations and clonality detection in lymphoproliferative disorders by capturebased Next-generation sequencing
Translocations and clonality detection in lymphoproliferative disorders by capturebased Next-generation sequencing Dörte Wren MSc MPhil on behalf of the EuroClonality-NGS consortium Molecular Diagnostics
More informationChronic lymphocytic leukemia is eradication feasible and worthwhile?
Chronic lymphocytic leukemia is eradication feasible and worthwhile? Gianluca Gaidano, MD, PhD Division of Hematology Department of Clinical and Experimental Medicine Amedeo Avogardo University of Eastern
More informationTest Utilization: Chronic Lymphocytic Leukemia
Test Utilization: Chronic Lymphocytic Leukemia Initial Evaluation Diagnostic Criteria Selection of Tests for Prognosis Response to Therapy Challenges Assessment for persistent disease Paul J. Kurtin, M.D.
More informationDr Prashant Tembhare
Dr Prashant Tembhare docprt@gmail.com FCM very powerful technology in Identification and characterization of neoplastic plasma cells as it allows - simultaneous assessment of multiple antigens large numbers
More informationUpdate on the International Harmonised Approach for Residual Disease Monitoring in Chronic Lymphocytic Leukaemia: 8-CLR flow cytometry
Update on the International Harmonised Approach for Residual Disease Monitoring in Chronic Lymphocytic Leukaemia: 8-CLR flow cytometry Andy C. Rawstron on behalf of ERIC consortium Timeline for development
More informationHOW CLONOSEQ TESTING WORKS HOW DO WE KNOW WHAT TO TRACK? track changes in the amount of residual disease over time
We identify, count, and track measurable residual disease (MRD) over time to provide helpful reports to your physician that inform your personalized treatment plan. 1 To do this, we: HOW CLONOSEQ TESTING
More informationFerrata Storti Foundation
Published Ahead of Print on November 30, 2009, as doi:10.3324/haematol.2009.018911. Copyright 2009 Ferrata Storti Foundation. Early Release Paper Enhanced sensitivity of flow cytometry for routine assessment
More informationMRD Evaluation The Austrian experience
MRD Evaluation The Austrian experience Gabriele Brachtl Molekularzytologisches Labor III. Medical Department of Hematology, Oncology, Hemostaseology, Rheumatology and Infectiology Head: Univ. Prof. Dr.
More informationClinical question. Screening tube. Diagnostic panel MRD. Clinical question
OW CYTOMETRY UPDATES IN LYMPHOPROLIFERATIVE DISORDERS CANCER RESEARCH CENTER IBSAL UNIVERSITY & UNIVERSITY HOSPITAL, SALAMANCA (SPAIN) DISCLOSURES The EuroFlow Scientific Consortium Iamco-chairof receives
More informationThe spectrum of flow cytometry of the bone marrow
The spectrum of flow cytometry of the bone marrow Anna Porwit Lund University Faculty of Medicine Dept. of Clinical Sciences Div. Oncology and Pathology anna.porwit@med.lu.se Disclosure of speaker s interests
More informationNGS IMMUNOGENETICS IN CLL RESEARCH. Andreas Agathangelidis Post-doc researcher Institute of Applied Biosciences, CERTH
NGS IMMUNOGENETICS IN CLL RESEARCH Andreas Agathangelidis Post-doc researcher Institute of Applied Biosciences, CERTH ERIC & Euroclonality-NGS workshop Rotterdam, 24 November 2017 1. NGS Immunoprofiling
More informationFlow cytometric analysis of B-cell lymphoproliferative disorders
Flow cytometric analysis of B-cell lymphoproliferative disorders David M. Dorfman, M.D., Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard Medical School Boston, MA Objectives Review
More informationComprehensive translocation and clonality detection in lymphoproliferative disorders by next generation sequencing
Comprehensive translocation and clonality detection in lymphoproliferative disorders by next generation sequencing Wren, D., Walker, B. A., Bruggemann, M., Catherwood, M. A., Pott, C., Stamatopoulos, K.,...
More informationMolecular Advances in Hematopathology
Molecular Advances in Hematopathology HOW MOLECULAR METHODS HAVE CHANGED MY PRACTICE Objectives Understand the importance of cytogenetic/molecular studies in hematolymphoid diseases Know some of the important
More informationNew IMWG Response Criteria
New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationMinimal residual disease of CLL in our everyday hematological practice
Minimal residual disease of CLL in our everyday hematological practice M. Doubek, J. Chovancová, B. Tichý, O. Stehlíková, H. Francová Skuhrová, M. Klabusay, K. Malinová, M. Krejčí, Y. Brychtová, Š. Pospíšilová,
More information2/4/14. Learning Objectives. Topics. Minimal Residual Disease After Stem Cell Transplantation. The current status
Minimal Residual Disease After Stem Cell Transplantation. The current status Sergio Giralt, MD Professor of Medicine Weill Cornell College of Medicine Chief, Adult BMT Service Memorial Sloan Kettering
More informationMRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
More informationMRD detection in AML. Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome
MRD detection in AML Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome Determinants of Treatment Response Leukemia Tumor burden Growth potential Drug resistance Karyotype Genetics Host
More informationNext-Generation Sequencing for the Assessment of Measurable Residual Disease
Next-Generation Sequencing for the Assessment of Measurable Residual Disease Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationSH/EAHP WORKSHOP 2017 CASE 210 PRESENTATION
SH/EAHP WORKSHOP 2017 CASE 210 PRESENTATION Jonathon H Gralewski DO, MS, Ginell R Post MD, PhD, Youzhong Yuan MD September 9, 2017 Clinical History 60 year old male with history of c-maf high-risk IgG
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationMRD in ALL: Correct interpretation in clinical practice. Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh
MRD in ALL: Correct interpretation in clinical practice Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh Minimal residual disease Subclinical level of residual leukemia Below
More informationSession 5. Pre-malignant clonal hematopoietic proliferations. Chairs: Frank Kuo and Valentina Nardi
Session 5 Pre-malignant clonal hematopoietic proliferations Chairs: Frank Kuo and Valentina Nardi Pre-malignant clonal hematopoietic proliferations Clonal LYMPHOID proliferations: - Monoclonal gammopathy
More informationMethods used to diagnose lymphomas
Institut für Pathologie Institut für Pathologie Methods used to diagnose lymphomas Prof. Dr.Med. Leticia Quintanilla-Fend Molecular techniques NGS histology Cytology AS-PCR Sanger seq. MYC Immunohistochemistry
More informationNCCN Guidelines for B-Cell Lymphomas V Update Meeting 08/14/18
DIAG-1 Submission request from Adaptive Biotechnologies to add NGS as an additional option to PCR for assessing IGH and TCR gene rearrangements under Essential Diagnosis: (immunohistochemistry, flow cytometry,
More informationTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version: CLLBiomarkers 1.0.0.2 Protocol Posting Date: June 2017
More informationCPAL and GenPath Flow Cytometry Specimen Handling
CPAL and GenPath Flow Cytometry Specimen Handling Lmphocyte Subset Analysis Peripheral Blood Bone Marrow Aspirates Surgical Biopsies Fine Needle Aspirate Biopsies Fluids Cerebral Spinal Fluid Bronchial
More informationSuccessful flow cytometric immunophenotyping of body fluid specimens
Successful flow cytometric immunophenotyping of body fluid specimens Fiona E. Craig, MD Division of Hematopathology Mayo Clinic Arizona 2017 MFMER slide-1 Financial disclosure No conflicts 2017 MFMER slide-2
More informationCriteria for Disease Assessment Joan Bladé
Criteria for Disease Assessment Joan Bladé Unidad de Amiloidosis y Mieloma Servicio de Hematología Hospital Clínic de Barcelona COMy Meeting, París, May 4th, 2018 Response Evaluation EBMT, 1998 - CR and
More informationThe development of clonality testing for lymphomas in the Bristol Genetics Laboratory. Dr Paula Waits Bristol Genetics Laboratory
The development of clonality testing for lymphomas in the Bristol Genetics Laboratory Dr Paula Waits Bristol Genetics Laboratory Introduction The majority of lymphoid malignancies belong to the B cell
More informationLymphoma Update: Lymphoma Update: What s Likely to be New in the New WHO. Patrick Treseler, MD, PhD University of California San Francisco
Lymphoma Update: What s Likely to be New in the New WHO Blood 127:2375; 2016 Patrick Treseler, MD, PhD University of California San Francisco Lymphoma Update: What IS New in the New WHO! Patrick Treseler,
More informationGenomic complexity and arrays in CLL. Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy
Genomic complexity and arrays in CLL Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy Clinical relevance of genomic complexity (GC) in CLL GC has been identified as a critical negative
More informationMultiparameter flow cytometry can be used to
Minimal residual disease testing in Acute Leukemia Anjum Hassan MD Assistant Professor of Pathology and Immunology, Director FISH laboratory in Anatomic Pathology, Washington University in St Louis, School
More informationDo Your Flow Cytometric LDTs. Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine
Do Your Flow Cytometric LDTs Conform to the ICSH ICCS Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine How should LDTs be validated? Accuracy Specificity Sensitivity
More informationFlow Cytometric Analysis of CD5+ B Cells A Frame of Reference for Minimal Residual Disease Analysis in Chronic Lymphocytic Leukemia
Hematopathology / CD5+ -CELL NLYSIS Y FLOW CYTOMETRY Flow Cytometric nalysis of CD5+ Cells Frame of Reference for Minimal Residual Disease nalysis in Chronic Lymphocytic Leukemia Ritu Gupta, MD, 1 Paresh
More informationMast Cell Disease Case 054 Session 7
Mast Cell Disease Case 054 Session 7 Rodney R. Miles, M.D., Ph.D. Lauren B. Smith, M.D. Cem Akin, M.D. Diane Roulston,, Ph.D. Charles W. Ross, M.D. Departments of Pathology and Internal Medicine University
More informationBCR-ABL1 Kinase Domain Mutation Status (including educational clinical scenario)
BCR-ABL1 Kinase Domain Mutation Status 171802 (including educational clinical scenario) Issue date: 23rd February 2018 Closing date: 23rd March 2018 Results for the BCR-ABL1 Kinase Domain Mutation Status
More informationIgCLL group activities in 2009 and beyond. Kostas Stamatopoulos Hematology Department and HCT Unit George Papanicolaou Hospital, Thessaloniki, Greece
IgCLL group activities in 2009 and beyond Kostas Stamatopoulos Hematology Department and HCT Unit George Papanicolaou Hospital, Thessaloniki, Greece Troubleshooting Standardization Standardization and
More informationImmunopathology of Lymphoma
Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.
More informationPeripheral blood Pleural effusion in a cat
Tools for the Diagnosis of Lymphoproliferative Diseases When is it difficult to diagnose lymphoproliferative disease? Persistent lymphocytosis consisting of small Lymph node aspirates containing an excess
More informationCLL Complete SM Report
Reported: 02/01/2012 Σ CGI ID No:5 Client:r Client Address: CLINICAL DATA: Lymphoma No CBC results provided. CLL Complete SM Report FINAL DIAGNOSIS: CD19+ B cell lymphoma, ZAP-70 + (44%), with borderline
More informationMinor H Antigen-Specific T Cells -The Black Box of the GVL Effect
Minor H Antigen-Specific T Cells -The Black Box of the GVL Effect All Allogeneic Stem Cell Transplants Are Blind Doctor Donor Patient Genetic polymorphism gives rise to unique peptides in donor and recipient
More informationMinimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment
MANTLE CELL LYMPHOMA Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment Eva Hoster 1 and Christiane Pott 2 1 Department of Internal Medicine III, University
More informationACCME/Disclosures 4/13/2016. Clinical History
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationGENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute
GENETIC MARKERS IN LYMPHOMA a practical overview P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute B and T cell monoclonalities Rearrangement of immunoglobin and TCR genes may help
More informationExtramedullary precursor T-lymphoblastic transformation of CML at presentation
Extramedullary precursor T-lymphoblastic transformation of CML at presentation Neerja Vajpayee, Constance Stein, Bernard Poeisz & Robert E. Hutchison Clinical History 30 year old man presented to the emergency
More informationPERSONALIZED MEDICINE IN LYMPHOMA: TAILORING TREATMENT ACCORDING TO MINIMAL RESIDUAL DISEASE
PERSONALIZED MEDICINE IN LYMPHOMA: TAILORING TREATMENT ACCORDING TO MINIMAL RESIDUAL DISEASE Authors: Irene Dogliotti and Simone Ferrero Division of Hematology, Department of Molecular Biotechnologies
More informationThe Development of Lymphocytes: B Cell Development in the Bone Marrow & Peripheral Lymphoid Tissue Deborah A. Lebman, Ph.D.
The Development of Lymphocytes: B Cell Development in the Bone Marrow & Peripheral Lymphoid Tissue Deborah A. Lebman, Ph.D. OBJECTIVES 1. To understand how ordered Ig gene rearrangements lead to the development
More informationMolecular Diagnosis. Nucleic acid based testing in Oncology
Molecular Diagnosis Nucleic acid based testing in Oncology Objectives Describe uses of NAT in Oncology Diagnosis, Prediction, monitoring. Genetics Screening, presymptomatic testing, diagnostic testing,
More informationDisclosures. Outlines. Plasma Cell Neoplasms 10/31/2017. I have nothing to disclose. Pei Lin, M. D. Updated diagnostic criteria (DD)
Plasma cell Neoplasms Disclosures I have nothing to disclose. Pei Lin, M. D. Outlines Updated diagnostic criteria (DD) Myeloma phenotype and MRD detection by MFC Identifying high risk patients MRD, FISH,
More informationCLL Ireland Information Day Presentation
CLL Ireland Information Day Presentation 5 May 2018 Professor Patrick Thornton Consultant Haematologist, Senior Lecturer RCSI, and Clinical Director Hermitage Medical Clinic Laboratory Chronic Lymphocytic
More informationDefined lymphoma entities in the current WHO classification
Defined lymphoma entities in the current WHO classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno Bellinzona, January 29-31, 2016 Evolution of lymphoma classification Rappaport Lukes
More informationMinimal residual disease. Bruno Paiva University of Navarra, Spain
Minimal residual disease Bruno Paiva University of Navarra, Spain 1st World Congress on Controversies in Multiple Myeloma. Bangkok, Thailand. May 11-13 214 Oprozomib (ONX 912) Phase I/II Autologous bone
More informationNucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis
Nucleic Acid Testing - Oncology Molecular Diagnosis Nucleic acid based testing in Oncology Gross alterations in DNA content of tumors (ploidy) Gain/Loss of nucleic acids Markers of Clonality Oncogene/Tumor
More informationTools for MRD in AML: flow cytometry
ACUTE MYELOID LEUKEMIA MEETING Ravenna - October 27, 2017 Tools for MRD in AML: flow cytometry Francesco Buccisano Can MRD improve outcome determina3on? No. of leukemic cells 10 12 10 10 10 8 10 6 10 4
More informationMeeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD
Meeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD What is it? clonal expansion of myeloid precursor cells with reduced capacity to differentiate as opposed to ALL/CLL, it is limited to the myeloid cell
More informationLLR Childhood Leukaemia CellBank Anne Thomson, CellBank Manager..org.uk
LLR Childhood Leukaemia CellBank Anne Thomson, CellBank Manager.org.uk Purpose To facilitate high quality translational research in childhood leukaemia: clinical and basic science Centralised specialist
More informationREPORT. KEY WORDS: Graft-versus-tumor, Minimal residual disease, Donor lymphocyte infusion
REPORT National Cancer Institute s First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations
More informationChronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationChronic Myeloid Leukaemia
Chronic Myeloid Leukaemia Molecular Response: What is really important? Jeff Szer The Royal Melbourne Hospital PROBABILITY, % PROBABILITY OF SURVIVAL AFTER MYELOABLATIVE TRANSPLANTS FOR CML IN CHRONIC
More informationMixed Phenotype Acute Leukemias
Mixed Phenotype Acute Leukemias CHEN GAO; AMY M. SANDS; JIANLAN SUN NORTH AMERICAN JOURNAL OF MEDICINE AND SCIENCE APR 2012 VOL 5 NO.2 INTRODUCTION Most cases of acute leukemia can be classified based
More informationOutlook CML 2016: What is being done on the way to cure
New Horizons 2011 Outlook CML 2016: What is being done on the way to cure Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA CML Working Party
More informationMBL in Blood Donors: An Extended Immunophenotypic Analysis of CLL-like, CD5+ MBL.
1 th Canadian CLL Meeting Winnipeg, Manitoba Inn at the Forks September 18-19, 214 MBL in Blood Donors: An Extended Immunophenotypic Analysis of CLL-like, CD5+ MBL. Fatima Abbasi 1, Justin Meskas 2, Ryan
More information2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228
2007 Workshop of Society for Hematopathology & European Association for Hematopathology Indianapolis, IN, USA Case # 228 Vishnu V. B Reddy, MD University of Alabama at Birmingham Birmingham, AL USA 11/03/07
More informationANCO: ASCO Highlights 2018 Hematologic Malignancies
ANCO: ASCO Highlights 2018 Hematologic Malignancies Brian A. Jonas, M.D., Ph.D. UC Davis Comprehensive Cancer Center August 25, 2018 Brian Jonas, MD, PhD ANCO: ASCO Highlights 2018 Relevant financial relationships
More informationThe Challenges of Precision Medicine: New Advances in Molecular Diagnostic Testing- Impact for Healthcare
The Challenges of Precision Medicine: New Advances in Molecular Diagnostic Testing- Impact for Healthcare Jessica Wang-Rodriguez, MD Chief, VISN22 Consolidated Pathology and Laboratory Medicine Services
More informationPh-like (BCR/ABL1-like): un apporoccio baato sul target molecolare
Ph-like (BCR/ABL1-like): un apporoccio baato sul target molecolare Sabina Chiaretti, MD PhD LE SFIDE DELLA MEDICINA DI PRECISIONE IN EMATOLOGIA Bologna 28 Giugno, 2018 Topics: BCR/ABL1-like and other subgroups
More informationDifferential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic
More informationCME/SAM. Flow Cytometric Immunophenotyping of Cerebrospinal Fluid Specimens
Hematopathology / Flow Cytometric Immunophenotyping of CSF Specimens Flow Cytometric Immunophenotyping of Cerebrospinal Fluid Specimens Fiona E. Craig, MD, 1 N. Paul Ohori, MD, 2 Timothy S. Gorrill, MD,
More informationIn-depth look at specific data-sets; which ones meet requirements? Individual data owners /cooperative groups
In-depth look at specific data-sets; which ones meet requirements? Individual data owners /cooperative groups Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) in transplant eligible
More informationADx Bone Marrow Report. Patient Information Referring Physician Specimen Information
ADx Bone Marrow Report Patient Information Referring Physician Specimen Information Patient Name: Specimen: Bone Marrow Site: Left iliac Physician: Accession #: ID#: Reported: 08/19/2014 - CHRONIC MYELOGENOUS
More informationPatient Selection for allogeneic stem cell transplantation in CLL KOEN VAN BESIEN, MD WEILL CORNELL MEDICAL COLLEGE, NY
Patient Selection for allogeneic stem cell transplantation in CLL KOEN VAN BESIEN, MD WEILL CORNELL MEDICAL COLLEGE, NY Topics CLL Complicated CLL Richter s transformation What did we learn about allotransplant
More informationCost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic
Cost-Effective Strategies in the Workup of Hematologic Neoplasm Karl S. Theil, Claudiu V. Cotta Cleveland Clinic In the past 12 months, we have not had a significant financial interest or other relationship
More informationMolecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU
Molecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU Lecture outline Time 10:00 11:00 11:15 12:10 12:20 13:15 Content Introduction to lymphoma Review of lymphocyte biology
More informationSupplementary Figure 1. Example of gating strategy
Supplementary Figure 1. Example of gating strategy Legend Supplementary Figure 1: First, gating is performed to include only single cells (singlets) (A) and CD3+ cells (B). After gating on the lymphocyte
More informationV. Acute leukemia. Flow cytometry in evaluation of hematopoietic neoplasms: A case-based approach
V. Acute leukemia Evaluating a sample for an acute leukemia Acute leukemia is a neoplasm of immature myeloid or lymphoid cells characterized by a block in maturation, usually at the stage of an early progenitor
More informationAggressive B-cell Lymphomas
Neoplastic Hematopathology Update 2018 Aggressive B-cell Lymphomas Raju K. Pillai City of Hope National Medical Center I do not have any disclosures Disclosures Outline New entities and changes in WHO
More informationHEMATOPATHOLOGY SUMMARY REPORT RL;MMR;
HEMATOPATHOLOGY SUMMARY REPORT RL;MMR; Page 1 of 1 05/15/20XX HP000000-20XX 05/21/20XX (212) 123-457 (51) 32-3455 (51) 123-457 Age: 78 DOB: 0/05/19XX SS#: 45-45-45 Clinical Information: 78 y/o female with
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationComparison of FISH, CpG-stimulation, chromosomal microarray and mate pair sequencing in 20 patients with CLL or lymphoma
Comparison of FISH, CpG-stimulation, chromosomal microarray and mate pair sequencing in 20 patients with CLL or lymphoma Stephanie Smoley Cancer Genomics Consortium August 9 th, 2017 2016 MFMER slide-1
More informationIs Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD
Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center
More informationIntegrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University
Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms Daniel A. Arber, MD Stanford University What is an integrated approach? What is an integrated approach? Incorporating all diagnostic
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationDr Shankara Paneesha. ASH Highlights Department of Haematology & Stem cell Transplantation
ASH Highlights 2015 Themes of ASH 2015 Novel therapies - Myeloma AML Lymphoma Pd-L1 & PD-l inhibitors Emerging concepts in biology HIF-1a pathway Cautionary tales ASH Choosing Wisely list IFM/DFCI
More informationVUmc Basispresentatie
Clinical diagnostic cytometry Gerrit J Schuurhuis Dept of Hematology VU University Medical Center Amsterdam, Netherlands Use of immunophenotyping at diagnosis to trace residual disease after therapy 1.
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationPersistent lymphocytosis. Persistent lymphocytosis: are there prognostic indicators? Problem. Questions. Basic markers used to identify lymphocytes
Persistent lymphocytosis Persistent lymphocytosis: are there prognostic indicators? Paul R. Avery VMD, PhD, DACVP Marjorie Williams, DVM Anne C. Avery VMD, PhD Clinical Immunology Laboratory Colorado State
More informationWe Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT
We Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT Danielle M. Brander, MD Duke University Division of Hematologic Malignancies & Cell Therapy CLL & Indolent
More informationPrimary Cutaneous CD30-Positive T-cell Lymphoproliferative Disorders
Primary Cutaneous CD30-Positive T-cell Lymphoproliferative Disorders Definition A spectrum of related conditions originating from transformed or activated CD30-positive T-lymphocytes May coexist in individual
More informationCLL & SLL: Current Management & Treatment. Dr. Peter Anglin
CLL & SLL: Current Management & Treatment Dr. Peter Anglin Chronic Lymphocytic Leukemia Prolonged clinical course Chronic A particular type of blood cell B lymphocyte Lymphocytic Cancer of white blood
More informationMEETING SUMMARY ASH 2018, San Diego, USA
MEETING SUMMARY ASH 2018, San Diego, USA Prof. Stefano Luminari University of Modena and Reggio Emilia, Italy AN UPDATE ON PROGNOSTIC FACTORS IN INDOLENT LYMPHOMAS 2 DISCLAIMER Please note: The views expressed
More informationCURRENT MOLECULAR DIAGNOSTICS IN HEMATOONCOLOGY
Third Slovenian congress of hematology and transfusion medicne, Podcetrtek, April 08 Third Slovenian congress of hematology and transfusion medicne, Podcetrtek, April 08 CURRENT MOLECULAR DIAGNOSTICS IN
More informationSystematic Reviews in Hematological Malignancies
Systematic Reviews in Hematological Malignancies Pia Raanani, MD Davidoff Cancer Center Rabin Medical Center, Israel 1 2 Disorder CHMG Systematic review* Title Protocol Full Review Myelodysplastic syndrome
More informationStem Cells And The Future of Regenerative Medicine. Dipnarine Maharaj, M. D., FACP
Stem Cells And The Future of Regenerative Medicine Dipnarine Maharaj, M. D., FACP The following potential conflict of interest relationships are germane to my presentation. Employment: South Florida Bone
More informationUse of MYC, BCL2 and BCL6 FISH for investigations of high grade B cell lymphoma
Use of MYC, BCL2 and BCL6 FISH for investigations of high grade B cell lymphoma Dr Anthony Bench Haematopathology and Oncology Diagnostic Service Cambrıdge Unıversıty Hospitals NHS Foundatıon Trust Cambridge
More informationDiagnostic Approach for Eosinophilia and Mastocytosis. Curtis A. Hanson, M.D.
Diagnostic Approach for Eosinophilia and Mastocytosis Curtis A. Hanson, M.D. 2014 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2014 MFMER slide-2 Molecular Classification
More information2013 AAIM Pathology Workshop
2013 AAIM Pathology Workshop John Schmieg, M.D., Ph.D. None Disclosures 1 Pathology Workshop Objectives Define the general philosophy of reviewing pathology reports Review the various components of Bone
More informationFramework for Defining Evidentiary Standards for Biomarker Qualification: Minimal Residual Disease (MRD) in Multiple Myeloma (MM)
Framework for Defining Evidentiary Standards for Biomarker Qualification: Minimal Residual Disease (MRD) in Multiple Myeloma (MM) MRD in Multiple Myeloma Team Biomarker Qualification Workshop Framework
More informationAbstract #163 Michael Kalos, PhD
LONG TERM FUNCTIONAL PERSISTENCE, B CELL APLASIA AND ANTI LEUKEMIA EFFICACY IN REFRACTORY B CELL MALIGNANCIES FOLLOWING T CELL IMMUNOTHERAPY USING CAR REDIRECTED REDIRECTED T CELLS TARGETING CD19 Abstract
More information